Your browser doesn't support javascript.
loading
Molecular alterations in sporadic pancreatic neuroendocrine microadenomas.
Hadano, Atsuko; Hirabayashi, Kenichi; Yamada, Misuzu; Kawanishi, Aya; Takanashi, Yumi; Kawaguchi, Yoshiaki; Nakagohri, Toshio; Nakamura, Naoya; Mine, Tetsuya.
Afiliação
  • Hadano A; Department of Gastroenterology and Hepatology, Tokai University School of Medicine, Japan.
  • Hirabayashi K; Department of Pathology, Tokai University School of Medicine, Japan. Electronic address: kenichi.hirabayashi@tokai.ac.jp.
  • Yamada M; Department of Surgery, Tokai University School of Medicine, Japan.
  • Kawanishi A; Department of Gastroenterology and Hepatology, Tokai University School of Medicine, Japan.
  • Takanashi Y; Department of Pathology, Tokai University School of Medicine, Japan.
  • Kawaguchi Y; Department of Gastroenterology and Hepatology, Tokai University School of Medicine, Japan.
  • Nakagohri T; Department of Surgery, Tokai University School of Medicine, Japan.
  • Nakamura N; Department of Pathology, Tokai University School of Medicine, Japan.
  • Mine T; Department of Gastroenterology and Hepatology, Tokai University School of Medicine, Japan.
Pancreatology ; 16(3): 411-5, 2016.
Article em En | MEDLINE | ID: mdl-26905832
ABSTRACT

BACKGROUND:

Pancreatic neuroendocrine microadenomas (pNEMAs) are neuroendocrine tumors measuring <5 mm in diameter. They are considered the precursor of pancreatic neuroendocrine tumors (pNETs). The aim of this study was to investigate the immunohistochemical differences between pNEMA, pNET, and hyperplasia of pancreatic islet cells (HPIL) in patients with non-familial syndromes.

METHODS:

We evaluated 21 pNEMAs, 19 HPILs, and 21 non-functional pNETs (10 G1 and 11 G2 cases) in patients with non-familial syndromes. Immunohistochemistry for tumor-associated markers death domain-associated protein (DAXX), alpha thalassemia/mental retardation X-linked (ATRX), cytokeratin 19 (CK19), bcl-2, and CD99 was performed.

RESULTS:

DAXX was expressed in 95%, 71%, and 71% of HPIL, pNEMA, and pNET samples, respectively; the differences were not significant. ATRX expression in pNEMA and pNET was significantly lower than that in HPIL, whereas there was no significant difference between pNEMA and pNET (HPIL 95%, pNEMA 43%, and pNET 52%). All HPIL and pNEMA cases were negative for bcl-2 and positive for CD99, whereas 29% of pNETs were positive for bcl-2 and 24% were negative for CD99. CK19 expression in HPIL was significantly lower than in pNEMA and pNET, although no significant difference was observed between pNEMA and pNET (HPIL 5%, pNEMA 57%, and pNET 43%). Among G1 and G2 pNETs, CD99 was expressed in 50% of G1 pNETs but not in any G2 pNET cases.

CONCLUSION:

Non-familial HPIL, pNEMA, and pNET patients exhibit distinct ATRX, CD99, CK19, and bcl-2 molecular profiles.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pâncreas / Neoplasias Pancreáticas / Biomarcadores Tumorais / Tumores Neuroendócrinos Idioma: En Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Japão

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pâncreas / Neoplasias Pancreáticas / Biomarcadores Tumorais / Tumores Neuroendócrinos Idioma: En Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Japão